Skip to main content

Table 2 Acute toxicities that occurred during preoperative treatment

From: The safety of an MRI simulation-guided boost after short-course preoperative radiotherapy for unresectable rectal cancer (SUNRISE): interim analysis of a randomized phase II trial

Toxicities

Experimental group N = 21 (%)

Control group N = 21 (%)

SCPRT

NCT

NCRT

Grade 1–2

Grade 3–4

Grade 1–2

Grade 3–4

Grade 1–2

Grade 3–4

Hematological

Total

6 (28.6)

0

14 (66.7)

2 (9.5)

10 (47.6)

1 (4.8)

Leukopenia

6 (28.6)

0

14 (66.7)

1 (4.8)

10 (47.6)

1 (4.8)

Thrombocytopenia

0

0

0

1 (4.8)

0

0

Neutropenia

0

0

3 (14.3)

0

1 (4.8)

0

Anemia

2 (9.5)

0

2 (9.5)

0

3 (14.3)

0

Non-Hematological

Total

12 (57.1)

4 (19.0)

14 (66.7)

2 (9.5)

16 (76.2)

3 (14.3)

Fatigue

3 (14.3)

0

3 (14.3)

0

7 (33.3)

0

Bleeding

6 (28.6)

0

2 (9.5)

0

7 (33.3)

0

Diarrhea

7 (33.3)

2 (9.5)

1 (4.8)

0

4 (19.0)

3 (14.3)

Abdominal distension

1 (4.8)

1 (4.8)

1 (4.8)

0

0

0

Anorexia

2 (9.5)

0

10 (47.6)

0

1 (4.8)

0

Nausea

3 (14.3)

0

10 (47.6)

1 (4.8)

2 (9.5)

0

Vomiting

1 (4.8)

0

7 (33.3)

1 (4.8)

0

0

Pain

8 (38.1)

4 (19.0)

3 (14.3)

1 (4.8)

13 (61.9)

1 (4.8)

Dermatitis

7 (33.3)

1 (4.8)

1 (4.8)

0

9 (42.9)

1 (4.8)

  1. SCPRT short-course preoperative radiotherapy; NCT neoadjuvant chemotherapy; NCRT neoadjuvant chemoradiotherapy